The roxadustat wrangling rumbles on

Snippets

Fibrogen and partners were probably hoping that the long-awaited cardiovascular safety analysis of the huge roxadustat clinical programme would silence concerns. But another highly critical report emerged yesterday; the authors are probably positioned to benefit from falling share prices, but it is notable that both Fibrogen and Astrazeneca moved to defend their data. The report concluded that roxadustat was unlikely to win approval in dialysis-dependent patients, pointing out that Pyrenees, a major trial that had the worst safety reading, had been omitted from the pooled analysis; it also claimed that the way the data were analysed understated the risk of death in this setting. Astrazeneca responded by saying the FDA had agreed to the Pyrenees exclusion, because of its different design; supportive equity analysts moved to defend other assertions of opaqueness. The sellside remains largely approving of Fibrogen, but roxadustat forecasts have come down substantially over the past 12 months. None of these debates will be settled until the regulatory verdicts are known, later next year, and until then many investors might decide to believe that there is no smoke without fire. Substantial postmarketing requirements are surely the best-case scenario here.

Sales forecasts for roxadustat, and how they've changed
Company Markets 2020e ($m)

2024e ($m)

12-mth chg in 2024 forecast
Astrazeneca WW ex Astellas regions, China co-promote with Fibrogen 160 893 -31%
Astellas Pharma Japan, Europe, CIS, Middle East & South Africa 86 387 -47%
Fibrogen WW royalties, China co-promote with Astra 32 155 -42%
  Total sales 278 1,436  
Source: EvaluatePharma.

 

Phase III roxadustat programme for US and EU regulators
Study  Primary sponsor Comparator  Location 
Dialysis dependent
Himalayas* Fibrogen Epogen US, Europe, RoW
Sierras* Fibrogen Epogen US, RoW
Rockies* Astrazeneca Epogen US, Europe, RoW
Pyrenees  Astellas  Epogen or Aranesp  EU only
Non-dialysis dependent 
Andes* Fibrogen Placebo  US, RoW
Olympus* Astrazeneca Placebo  US, Europe, RoW
Alps* Astellas  Placebo  Europe, RoW
Dolomites  Astellas  Aranesp Europe, RoW
*Included in Mace analysis for US FDA.

Share This Article